October 2015

Rheonix Inc. Raises $28.6 Million to Further Expand Commercialization Efforts of Molecular Diagnostic Technology

ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, raised $28.6 million to further expand the company’s commercialization efforts for its breakthrough molecular testing platforms, the Encompass MDx® and Encompass Optimum™. The investment will also enable new product development and fund existing business needs. The funds are a combination of investments from existing international and domestic investors. Domestic investors include Advantage Capital Partners, Cayuga Venture Fund,… Read More »

Rheonix to Host Workshop and Showcase Easy-to-Use, Cost-Effective Molecular Diagnostic Technology at AMP 2015

ITHACA, N.Y. – Rheonix Inc., a developer of fully automated molecular testing solutions, will host a workshop at the Association for Molecular Pathology (AMP) 2015 Annual Meeting, which will be held Nov. 4-7 at the Austin Convention Center in Austin, Texas. The workshop, “Meeting the Challenges of the Changing LDT Landscape: Tools for Compliance,” will take place at 12 p.m., Nov. 4 in room 18B at the Convention Center. Throughout… Read More »